Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00016302 · ClinicalTrials.gov registry record · NA
Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
A NA study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- NA
- Development phase
- 100
- Enrollment target
NCT00016302: Completed NA study, sponsored by National Cancer Institute (NCI).
NCT00016302 is a NA study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 100 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00016302, a NA study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
Study Summary
Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. This phase II trial is studying several different combination chemotherapy regimens to see how well they work in treating patients with newly diagnosed acute lymphoblastic leukemia
Interventions
- DRUG prednisone
- DRUG methotrexate
- DRUG vincristine sulfate
- DRUG asparaginase
- DRUG daunorubicin hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2001-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00016302
The ClinicalTrials.gov registry entry for NCT00016302 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which prednisone is the first listed.
NCT00016302 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00016302 about?
NCT00016302 is a clinical study titled "Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia". Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. This phase II trial is studying several different combination chemotherapy regimens to see how well they work in treating patients wi...
What is the current status of trial NCT00016302?
This trial is currently completed. It is a NA study. The enrollment target is 100 participants. The study started on 2001-04.
What interventions are being tested in trial NCT00016302?
The interventions under investigation include: prednisone (DRUG), methotrexate (DRUG), vincristine sulfate (DRUG), asparaginase (DRUG), daunorubicin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00016302?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.